Antibiotics

It is produced by the strain of Str. hygroscopicus B-5050. It's a macrolide antibiotic. It has the activity against gram-positive bacteria and mycoplasma. Serum dose not affect its antibacterial activity. It has the effect of protecting gram-positive bacterial infection mice, and the therapeutic dose is similar to styloleomycin.

It is produced by the strain of Str. hygroscopicus B-5050. It's a macrolide antibiotic. It has the activity against gram-positive bacteria and mycoplasma. Serum dose not affect its antibacterial activity. It has the effect of protecting gram-positive bacterial infection mice, and the therapeutic dose is similar to styloleomycin.

It is produced by the strain of Act. sp. HIL Y-862O. It has an inhibitory effect on pathogenic fungi. It inhibits the Phytophthora infestans JO8 in vitro (MIC is 7.8 μg/mL), and it inhibits JO8 in greenhouse (LD50 is 42 X 10-6, LC90 is 500 X 10-6).

It is produced by the strain of Act. sp. HIL Y-862O. It has an inhibitory effect on pathogenic fungi. It inhibits the Phytophthora infestans JO8 in vitro (MIC is 7.8 μg/mL), and it inhibits JO8 in greenhouse (LD50 is 42 X 10-6, LC90 is 500 X 10-6).

It is produced by the strain of Micromonospora megalomice var. megalomicea NRRL 3274. It is a macrolide antibiotic. It has anti-bacterial and mycobacterium activity, the activity is the strongest under alkaline condition, serum can reduce the activity of 20%-30%. It has protective effect on mice infected with Staphylococcus aureus or pneumococcus.

It is produced by the strain of Micromonospora megalomice var. megalomicea NRRL 3274. It is a macrolide antibiotic. It has anti-bacterial and mycobacterium activity, the activity is the strongest under alkaline condition, serum can reduce the activity of 20%-30%. It has protective effect on mice infected with Staphylococcus aureus or pneumococcus.

It is produced by the strain of Micromonospora megalomice var. megalomicea NRRL 3274. It is a macrolide antibiotic. It has anti-bacterial and mycobacterium activity, the activity is the strongest under alkaline condition, serum can reduce the activity of 20%-30%. It has protective effect on mice infected with Staphylococcus aureus or pneumococcus.

It is produced by the strain of Myxococcus flavescens No. 154. It has the effect against subtilis and Escherichia coli. Megovalicin H shows the strongest antibacterial activity among the 6 components.

It is produced by the strain of Myxococcus flavescens No. 154. It has an effect against subtilis and Escherichia coli, and it also has the effect against Pseudomonas aeruginosa. Megovalicin H shows the strongest antibacterial activity among the 6 components.

It is produced by the strain of Myxococcus flavescens No. 154. It has an effect against subtilis and Escherichia coli, and it also has the effect against Pseudomonas aeruginosa. Megovalicin H shows the strongest antibacterial activity among the 6 components.

Ossamycin is a macrolide antibiotic produced by the strain of Str. hygroscopicus, Var. ossamyceticus C 8158. It has anti-fungal effect, and it has weaker anti-gram-positive bacterial effect. It inhibits L cells, Epstein-Barr ascites cancer cells, KB cells, sarcoma-180 cells, L-1210 cells, HeLa cells in cell culture with IC50s (μg/mL) of 0.007, 0.008, 0.005, 0.008, 0.003, 0.005, respectively. It has no antitumor effect in in vivo animal test.

It is produced by the strain of Str. ostreogriseus NRRL 2558 (NCIB 8792). It has anti-gram positive bacterial activity, and Ostreogrycin A has stronger antibacterial activity than other components. Ostreogrycin A or G has synergistic antibacterial effect with each component of Ostreogrycin B. The Complex has protective effect on mice infected with bacteria by subcutaneous or oral administration.

It is produced by the strain of Oudemansiella sp. 10F. It is an oxygen-containing heterocyclic antibiotic. It has weak antibacterial and fungal activity. Oudenone of more than 3.13 mg/kg has antihypertensive effect on spontaneous hypertension in rats by intraperitoneal injection or oral administration.

Oxamicetin is produced by the strain of Arthrobacter oxamicetus B 302-B 75. It's a nucleoside antibiotic. It has anti-bacterial, mycobacterium effects. It has protective effect on intramuscular injection in mice infected with Staphylococcus aureus and Escherichia coli, but oral administration is not effective. It inhibits pathogenic leptospirosis at 0.1-0.5 μg/mL, and inhibits non-pathogenic leptospirosis at 10-40 μg/mL.

It is produced by the strain of Str. capreolus MG 265-CF3. It's a nucleoside antibiotic. It has weak anti-gram-negative effect on peptone AGAR medium but no antibacterial effect on nutrient AGAR medium. It has antagonistic effect on guanine, guanosine and 5'-guanidine. In vitro, it inhibits HeLa cells with IC50 of 32 mg/kg. In mice, it has inhibitory effect on the leukemia L-1210.

It is produced by the strain of Vaginatispora aquatica HK 1821. It has medium activity against gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant enterococcus faecalis (MIC is 16 μg/mL). It has no activity against gram-negative bacteria and fungi.

It is produced by the strain of Pseudomonas sp. QN05727. It's an anti-tumor antibiotic. It can selectively inhibit the growth of 3Y1 in rat fibroblasts with degeneration of various tumor genes. It inhibits v-H-ras-3Y1, v-src-3Y1 cells and the normal 3Y1 cells with IC50 (nmol/L) of 14, 4.5 and 140, respectively. It stops RAS-or SRC-denatured cells at G1 phase of the cell cycle and increases p21WAF1 expression.

It is produced by the strain of Beauveria felina SANK 136. It has anti-gram-positive bacteria and Mycobacterium activity, but the antibacterial activity is weak.

It is produced by the strain of Pseudomonas chlororaphis. It is an antibiotic with activity against gram-positive bacteria.

Oxypyrrolnitrin is produced by the strain of Pseudomonas pyrrolnitrica. It is a nitrogen-containing heterocyclic antibiotic. It has anti-gram-positive bacteria, negative bacteria, mycobacterium and fungal effects.